2023 International Congress » Clinical Trials and Therapy in Movement Disorders (non-PD) (non-Dystonia)

Meeting: 2023 International Congress

A multiple-dose thorough QT study to evaluate the effect of ampreloxetine on cardiac repolarization in healthy subjects

M. Borin, J. Kanodia, R. Graham, A. Lo, B. Zheng, D. Bourdet (South San Francisco, USA)

A randomized, phase 2a, double-blind, placebo-controlled clinical trial with NE3107 adjunctive to carbidopa/levodopa in patients with Parkinson’s disease

J. Aldred, R. Rodriguez, E. Rivera-Rivera, S. Isaacson, R. Kumar, A. Ellenbogen, C. Ahlem, C. Reading, J. Palumbo, N. Osman, A. Lang (Spokane, USA)

An Analysis of Subgroups of Multiple System Atrophy Patients from Ampreloxetine Phase 3 Trials

R. Freeman, I. Biaggioni, L. Norcliffe-Kaufmann, T. Guerin, R. Vickery, L. Manzanares, V. Iodice, M. Rudzińska-Bar, M. Pellecchia, H. Kaufmann (Boston, USA)

Baseline characteristics for patients with multiple system atrophy entering a randomized, controlled study of the anti-α-synuclein monoclonal antibody Lu AF82422

W. Singer, A. Takeda, L. Kjærsgaard, J. Wiedemann, A. Berger, A. Varrone, A. Bidani, D. Meulien (Rochester, USA)

Brain-behavior quantification and synchronization to drive closed-loop deep brain stimulation

A. Gunduz, D. Johnson, M. Okun, K. Foote (Gainesville, USA)

Circuit-based targeting for closed-loop deep brain stimulation for Tourette Syndrome

C. Butson, A. Gunduz, K. Foote, E. Mahoney-Rafferty, J. Gomez, M. Hook, J. Cagle, G. Lowor, U. Suryadevara, D. Bowers, I. Malaty, W. Allen, M. Okun (Gainesville, USA)